Pulse Biosciences Presents Six-Month Interim Results From PRECISE-BTN Thyroid Nodule Study, At 95th ATA Annual Meeting

86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events 

Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs). The results were presented at the 95th Annual Meeting of the American Thyroid Association (ATA), held November 4–7, 2026, in Philadelphia.

For this interim dataset, 43 patients treated at three U.S. centers had reached the six-month assessment for the study's primary endpoint. Key findings include:

• Nodule volume reduction: 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction at six months. Median volume reduction was 72% at six months, with the majority of reduction evident by the one-month visit and continuing to improve over time.
• Quality of life and symptomatic relief: The ThyPRO-39 Overall Quality of Life Impact score improved by 78% from baseline at six months. Among patients who reported neck pressure or fullness at baseline, the symptom had fully resolved in 82% of patients at six months.
• Safety: No serious adverse events were reported.